Trends in prostate cancer incidence, hospital utilization and surgical procedures, Canada, 1981-2000

Canadian Journal of Public Health

Volumn 97, Issue 3, 2006, Pages 177-182

  Neutel, C Ineke ^a,b   Gao, Ru Nie ^a   Blood, Paul A ^c   Gaudette, Leslie A ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Hospital utilization; Orchiectomy; Prostate cancer; Prostatectomy; Surgery; Trends

Indexed keywords

ADULT; AGED; AMBULATORY SURGERY; ARTICLE; CANADA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SCREENING; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; HEALTH PROGRAM; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL SERVICE; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE; TRANSURETHRAL RESECTION;

EID: 33745897106     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405579     Document Type: Article

References (33)

1. National Cancer Institute of Canada. Canadian Cancer Statistics, 2004. Toronto, ON: Author, 2004.
2. National Cancer Institute of Canada. Canadian Cancer Statistics, 1996. Toronto: Author, 1996.
3. Gibbons L, Waters C. Prostate cancer - testing, incidence, surgery and mortality. Health Reports 2003;14:9-20.
4. Levy IG, Iscoe NA, Klotz LH. Prostate cancer: 1. The descriptive epidemiology in Canada. CMAJ 1998;159:509-13.
5. Skarsgard D, Tonita J. Prostate cancer in Saskatchewan, Canada, before and during the PSA era. Cancer Causes Control 2000;11:79-88.
6. Cookson MM. Prostate cancer: Screening and early detection. Cancer Control 2001;8:133-40.
7. Feuer EJ, Mariotti A, Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer 2002;95:870-80.
8. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. JNCI 1999;91:1017-24.
9. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (pred. Oncol.) 2000;85:60-67.
10. Ellison LF, Stokes J, Gibbons L, Lindsay J, Levy I, Morrison H. Monograph series on aging-related diseases: X. Prostate cancer. Chron Dis Can 1998;19:1-18.
11. Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: Interpreting trends in prostate cancer - Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. JNCI 1999;91:1033-39.
12. McGregor M, Hanley JA, Boivin J-F, McLean RG. Screening for prostate cancer: Estimating the magnitude of over detection. CMAJ 1998;159:1368-72.
13. Draaisma G, De Koning HJ. MISCAN: Estimating lead-time and over-detection by simulation. BJU International 2003; 92:(Suppl. 2):106-11.
14. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from US prostate cancer incidence trends. JNCI 2002;94:981-90.
15. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001;23:181-86.
16. Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: Forecasts from the Montreal Prostate Cancer Model. CMAJ 2000;162:987-92.
17. Neutel CI, Gao R-N, Gaudette LA, Johansen HL. Shorter hospital stays for breast cancer. Health Rep 2004;16:19-31.
18. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000;88:1122-30.
19. Alibhai SM, Krahn MD, Cohen MM, Fleshner NE, Tomlinson GA, Naglie G. Is there age bias in the treatment of localized prostate carcinoma? Cancer 2004;100:72-81.
20. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003;21:4001-8.
21. Alibhai SMH, Naglie G, Nam R, Trachtenberg J, Krahn MD. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003;21:3318-27.
22. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Data Base Report on prostate carcinoma after the peak in incidence rates in the U.S. Cancer 1998;83(8):1679-84.
23. Wingo PA, Guest JL, McGinnis L, Gort EH, Fleshner NE, Paszat LF, Browman GP. Patterns of inpatient surgeries for the top four cancers in the United States, National Hospital Discharge Survey, 1988-95. Cancer Causes Control 2000;11:497-512.
24. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-49.
25. Bondy SJ, Iscoe NA, Rothwell DM, Gort EH, Fleshner NE, Paszat LF, Browman GP. Trends in hormonal management of prostate cancer: A population-based study in Ontario. Med Care 2001;39:384-96.
26. Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999;150:848-60.
27. Adolfsson J, Steineck G, Hedlund P-O. Deferred treatment of clinically localized low-grade cancer: Actual 10-year and projected 15-year follow-up of the Karolinska series. Urol 1997;50:722-26.
28. Beaulac JA, Fry RN, Onysko J. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006;97(3):171-76.
29. Bunting PS, Goel V, Williams J, Iscoe NA. Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer. CMAJ 1999;160:70-75.
30. Feightner JW. Screening for prostate cancer. In: Canadian Taskforce on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa, ON: Health Canada, 1994; 812-23.
31. Ramsey EW. Early detection of prostate cancer. Recommendations from the Canadian Urological Association. Can J Oncol 1994;4 Suppl 1:82-85.
32. BC Cancer Agency. Evaluation of screening for prostate cancer with PSA. 2001. Available online at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/default.htm (Accessed April 11, 2006).
33. Canadian Cancer Society. Early detection and screening for prostate cancer. Available online at: http://www.cancer.ca (Accessed April 11, 2006).